PHARVARIS N.V. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.14 USD | -1.52% |
|
-17.17% | -35.33% |
| Apr. 15 | Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating | MT |
| Apr. 12 | Pharvaris Files Mixed Shelf | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 930M 991M |
|---|---|---|---|---|---|
| Net income 2024 * | -115M -123M | Net income 2025 * | -136M -145M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 282M 300M | Net cash position 2025 * | 161M 172M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-7.51
x | P/E ratio 2025 * |
-7.16
x | Employees | 82 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pharvaris N.V.
More recommendations
More press releases
| 1 day | -13.11% | ||
| 1 week | -17.44% | ||
| Current month | -20.29% | ||
| 1 month | -25.82% | ||
| 3 months | -35.50% | ||
| 6 months | -6.97% | ||
| Current year | -34.33% |
1 week
18.33
21.75
1 month
18.3326.49
Current year
18.3333.00
1 year
7.9333.00
3 years
1.7733.00
5 years
1.7742.86
10 years
1.7742.86
| Managers | Title | Age | Since |
|---|---|---|---|
Anne Lesage
FOU | Founder | 63 | 15-09-29 |
| Founder | 65 | 15-09-29 | |
Stefan Abele
CTO | Chief Tech/Sci/R&D Officer | 55 | Nov. 14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 65 | 15-09-29 | |
David Meeker
CHM | Chairman | 69 | 20-12-31 |
Robert Glassman
BRD | Director/Board Member | 62 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 18.14 | -1.52% | 60 401 |
| 24-04-18 | 18.42 | -13.11% | 69,471 |
| 24-04-17 | 21.2 | +0.95% | 327,306 |
| 24-04-16 | 21 | +4.22% | 64,230 |
| 24-04-15 | 20.15 | -7.99% | 167,186 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
17.27
EUR
Average target price
31.03
EUR
Spread / Average Target
+79.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.33% | 991M | |
| -1.82% | 41.35B | |
| +42.04% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- PHVS Stock
